Authorship note: rwc and zab contributed equally to this work. conflict of interest: zab, dma, dhk, wss, lac, and lz are employees of and shareholders in mapp biopharmaceutical, inc. dpp and eb are employees and shareholders of gilead sciences, inc

HIGHLIGHTS

• who: Robert W. Cross and colleagues from the Galveston National LaboratoryUniversity of California, USA have published the paper: Authorship note: RWC and ZAB contributed equally to this work. Conflict of interest: ZAB, DMA, DHK, WSS, LAC, and LZ are employees of and shareholders in Mapp Biopharmaceutical, Inc. DPP and EB are employees and shareholders of Gilead Sciences, Inc, in the Journal: (JOURNAL)
• how: The authors investigated the therapeutic efficacy of a once-daily 12-dose remdesivir regimen in a near uniformly lethal rhesus macaque model of SUDV infection.

SUMMARY

Filoviruses (family . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.